Grunnleggende statistikk
| CIK | 1016504 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Integrated BioPharma, Inc.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 14, 2025 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 14, 2025 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Exhibit 99.1 NEWS RELEASE for May 14, 2025 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 HILLSIDE, NEW JERSEY (May 14, 2025) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2025. Revenue for the qua |
|
| April 24, 2025 |
Letter from Marcum LLP to the Securities and Exchange Commission, dated April 24, 2025 Exhibit 16.1 April 24, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Integrated BioPharma, Inc. under Item 4.01 of its Form 8-K dated April 24, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Integrated BioPharma, Inc. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 24, 2025 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSI |
|
| April 21, 2025 |
Exhibit 10.1 Loan Agreement THIS LOAN AGREEMENT (the “Agreement”), is entered into as of April 9, 2025, between INTEGRATED BIOPHARMA, INC., a Delaware corporation, with an address at 225 LONG AVENUE, SUITE 15, HILLSIDE, NEW JERSEY 07205-2356, and MANHATTAN DRUG COMPANY, INC., a New Jersey corporation, with an address at 225 LONG AVENUE, SUITE 15, HILLSIDE, NEW JERSEY 07205-2356 (individually and c |
|
| April 21, 2025 |
Exhibit 10.2 Revolving Line of Credit Note (Daily SOFR) $4,000,000.00 April 15, 2025 FOR VALUE RECEIVED, INTEGRATED BIOPHARMA, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 07205-2356 and MANHATTAN DRUG COMPANY, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 07205-2356 (individually and collectively, the “Borrower”), promises to pay to the order of PNC BA |
|
| April 21, 2025 |
Exhibit 10.4 Security Agreement THIS SECURITY AGREEMENT (this “Agreement”), dated as of April 15, 2025, is made by and between INTEGRATED BIOPHARMA, INC. (the “Grantor”), with an address at 225 LONG AVE, STE 15, HILLSIDE, NJ 07205-2356, and PNC BANK, NATIONAL ASSOCIATION (the “Bank”), with an address at 150 Clove Rd, Little Falls, NJ 07424-2138. Under the terms hereof, the Bank desires to obtain a |
|
| April 21, 2025 |
Exhibit 10.3 Convertible Equipment Line of Credit Note (Daily SOFR) $500,000.00 April 15, 2025 FOR VALUE RECEIVED, INTEGRATED BIOPHARMA, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 07205-2356 and MANHATTAN DRUG COMPANY, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 07205-2356 (individually and collectively, the “Borrower”), promises to pay to the order |
|
| April 21, 2025 |
Exhibit 10.6 Reimbursement Agreement for Standby and Commercial Letter(s) of Credit THIS REIMBURSEMENT AGREEMENT FOR STANDBY AND COMMERCIAL LETTER(S) OF CREDIT (this “Agreement”) is made as of April 15, 2025, by INTEGRATED BIOPHARMA, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 07205-2356 and MANHATTAN DRUG COMPANY, INC., with an address at 225 LONG AVE, STE 15, HILLSIDE, NE |
|
| April 21, 2025 |
Exhibit 10.5 Security Agreement THIS SECURITY AGREEMENT (this “Agreement”), dated as of April 15, 2025, is made by and between MANHATTAN DRUG COMPANY, INC. (the “Grantor”), with an address at 225 LONG AVE, STE 15, HILLSIDE, NJ 07205-2356, and PNC BANK, NATIONAL ASSOCIATION (the “Bank”), with an address at 150 Clove Rd, Little Falls, NJ 07424-2138. Under the terms hereof, the Bank desires to obtain |
|
| April 21, 2025 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 15, 2025 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSI |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 13, 2025 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| February 13, 2025 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 NEWS RELEASE for February 13, 2025 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| December 2, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 2, 2024 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 13, 2024 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 14, 2024 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 Exhibit 99.1 NEWS RELEASE for November 13, 2024 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 HILLSIDE, NEW JERSEY (November 13, 2024) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2024. Rev |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| September 23, 2024 |
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2024 Exhibit 99.1 NEWS RELEASE for September 20, 2024 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2024 HILLSIDE, NEW JERSEY (September 20, 2024) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal yea |
|
| September 23, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 20, 2024 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMM |
|
| September 20, 2024 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K __ __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| May 10, 2024 |
EXHIBIT 10.2 AMENDED AND RESTATED REVOLVING CREDIT NOTE PNC Bank, National Association $5,000,000 May 9, 2024 Woodbridge, N.J. This Amended and Restated Revolving Credit Note (this “Note”) is executed and delivered under and pursuant to the terms of that certain Revolving Credit, Term Loan and Security Agreement dated as of June 27, 2012 (as amended, restated, supplemented or modified from time to |
|
| May 10, 2024 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024 NEWS RELEASE for May 10, 2024 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024 HILLSIDE, NEW JERSEY (May 10, 2024) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters e |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 10, 2024 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 10, 2024 |
Exhibit 10.1 FIFTH AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into May 9, 2024 by and among INTEGRATED BIOPHARMA, INC., a corporation organized under the laws of the State of Delaware (“Integrated”), MANHATTAN DRUG COMPANY, INC. (successor-by-merger to InB:MANHATTAN DRUG CO |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| February 12, 2024 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023 NEWS RELEASE for February 12, 2024 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| February 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 12, 2024 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 27, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 27, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 16, 2023 |
INBP / Integrated BioPharma, Inc. / INTEGRATED BIOPHARMA INC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. ) Under the Securities Exchange Act of 1934 Integrated BioPharma, Inc. (Name of Issuer) Common Stock, par value $.002 (Title of Class of Securities) 45811V (CUSIP Number) Heidi Kay Heidi Kay 703 Peach Tree Lane Franklin Lakes, NJ 07417 (646) 262-0663 (Name, Address and Telephone Number of Person Aut |
|
| November 14, 2023 |
INBP / Integrated BioPharma, Inc. / INTEGRATED BIOPHARMA INC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. ) Under the Securities Exchange Act of 1934 Integrated BioPharma, Inc. (Name of Issuer) Common Stock, par value $.002 (Title of Class of Securities) 45811V (CUSIP Number) Edward Gerald Kay Estate c/o Christina Kay, Co-Executor 40 E 9th St, Apt 2K New York, NY 10003 (646) 262-0663 (Name, Address and |
|
| November 14, 2023 |
EX-99.1 2 ex596378.htm EXHIBIT 99.1 JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $.002 per share, of Integrated BioPharma, I |
|
| November 9, 2023 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023 Exhibit 99.1 NEWS RELEASE for November 9, 2023 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023 HILLSIDE, NEW JERSEY (November 9, 2023) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2023. Reven |
|
| November 9, 2023 |
9UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q 9UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHA |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 9, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| September 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 15, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMM |
|
| September 15, 2023 |
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023 Exhibit 99.1 NEWS RELEASE for September 15, 2023 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023 HILLSIDE, NEW JERSEY (September 15, 2023) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal yea |
|
| September 15, 2023 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K __ __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2023 ☐ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| May 11, 2023 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2023 NEWS RELEASE for May 11, 2023 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2023 HILLSIDE, NEW JERSEY (May 11, 2023) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2023. Revenue for the quarter ended Marc |
|
| May 11, 2023 |
EXHIBIT 10.1 EXECUTION VERSION FOURTH AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into March 16, 2023 by and among INTEGRATED BIOPHARMA, INC., a corporation organized under the laws of the State of Delaware (“Integrated”), MANHATTAN DRUG COMPANY, INC. (successor-by-merger t |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 11, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 20, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSI |
|
| March 21, 2023 |
Integrated BioPharma Announces the Sudden Death of Its Executive Chairman and President NEWS RELEASE for March 21, 2023 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 16, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSI |
|
| February 10, 2023 |
STANDARD FORM OF LOFT LEASE This Lease, dated November 22, 2022 is made between Elizabeth Industrial Park, LLC c/o Palin Enterprises, having offices at 235 Park Avenue South, 8th floor, New York, New York 10003-1405 (hereinafter referred to as “Landlord”) and MDC Warehousing and Distribution, Inc. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| February 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 10, 2023 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| February 10, 2023 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2022 NEWS RELEASE for February 10, 2023 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 1, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| November 28, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 28, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 10, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 14, 2022 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 EX-99.1 2 ex447295.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1 NEWS RELEASE for November 10, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial res |
|
| November 14, 2022 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 Exhibit 99.1 NEWS RELEASE for November 10, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the ?Company? or ?INBP?) reports its financial results for the quarter ended September 30, 2022. Rev |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 10, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COM |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confiden |
|
| October 24, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 21, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| October 24, 2022 |
Letter from Friedman LLP to the Securities and Exchange Commission, dated October 24, 2022 EXHIBIT 16.1 October 24, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Integrated BioPharma, Inc. under Item 4.01 of its Form 8-K dated October 24, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Integrated BioPharma, I |
|
| September 14, 2022 |
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2022 Exhibit 99.1 NEWS RELEASE for September 13, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2022 HILLSIDE, NEW JERSEY (September 13, 2022) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the ?Company? or ?INBP?) reports its financial results for the quarter and fiscal yea |
|
| September 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 13, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMM |
|
| September 13, 2022 |
Exhibit 10.2.2 Agreement to Cancel Lease This Agreement to cancel lease (the ?Agreement?) is made and effective July 1, 2022, BETWEEN: Vitamin Realty Associates LLC (the ?Landlord?), with offices located at 225 Long Avenue, Hillside, NJ 07205 AND: Agrolabs, Inc. (the ?Tenant?), with offices located at 225 Long Avenue, Hillside, NJ 07205 WHEREAS the Landlord and the Tenant executed a lease dated Ma |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K __ __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2022 ? Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| September 13, 2022 |
Exhibit 10.1.2 THIRD AMENDMENT OF LEASE This THIRD AMENDMENT OF LEASE (this "Amendment") is made as of the 15th day of July 2022, between VITAMIN REALTY ASSOCIATES LLC (the LESSOR"), a New Jersey limited liability company, and MANHATTAN DRUG COMPANY, INC (the LESSEE"), a New Jersey corporation, having an address at 225 Long Avenue, Hillside, New Jersey 07205. WITNESSETH WHEREAS, pursuant to that c |
|
| September 13, 2022 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| July 15, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 15, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSIO |
|
| June 21, 2022 |
Integrated BioPharma Announces Change in Directors NEWS RELEASE for June 21, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Announces Change in Directors HILLSIDE, NEW JERSEY (June 21, 2022) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the ?Company? or ?INBP?) announced today Mr. Carl DeSantis has resigned as a Class I Director from the Company?s Board of Directors and Mr. Damon |
|
| June 21, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 20, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSIO |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| May 12, 2022 |
Integrated BioPharma, Inc. & its subsidiaries Code of Conduct and Ethics The following Code of Conduct and Ethics Policy applies to all agents, employees, directors, contractors, interns and volunteers of Integrated BioPharma, Inc., and its subsidiaries, referred to as ?members?. The Company is committed to a work environment that prohibits human trafficking, illegal or harmful child labor, compul |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 11, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 12, 2022 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2022 NEWS RELEASE for May 12, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2022 HILLSIDE, NEW JERSEY (May 12, 2022) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the ?Company? or ?INBP?) reports its financial results for the fiscal quarter ended March 31, 2022. Revenue for the three-mon |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 10, 2022 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| February 10, 2022 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2022 NEWS RELEASE for February 10, 2022 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| November 29, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 29, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 10, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| November 10, 2021 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2021 Exhibit 99.1 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2021 HILLSIDE, NEW JERSEY (November 10, 2021) - Integrated BioPharma, Inc. (OTCQX: INBP) (the ?Company? or ?INBP?) reports its financial results for the quarter ended September 30, 2021. Revenue for the quarter ended September 30, 2021 was $12.8 million compared to $15.2 million for the quarter ended September 30 |
|
| October 27, 2021 |
DEF 14A 1 inbp20211020def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate |
|
| September 2, 2021 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| September 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 2, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| September 2, 2021 |
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2021 NEWS RELEASE for September 2, 2021 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2021 ☐ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| July 7, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 30, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSIO |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 13, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 13, 2021 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021 NEWS RELEASE for May 13, 2021 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021 HILLSIDE, NEW JERSEY (May 13, 2021) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the ?Company? or ?INBP?) reports its financial results for the quarter ended March 31, 2021. Revenue for the quarter ended Ma |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q 10-Q 1 inbp2021033110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numb |
|
| April 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 8, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSIO |
|
| April 8, 2021 |
Integrated BioPharma Announces Launch of Investors Website NEWS RELEASE for April 8, 2021 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Announces Launch of Investors Website HILLSIDE, NEW JERSEY (April 8, 2021) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the ?Company? or ?INBP?) announces the launch of an updated investors website. ?As part of our efforts in supporting Integrated BioPharma, |
|
| February 12, 2021 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2020 EX-99.1 2 ex226080.htm EXHIBIT 99.1 PRESS RELEASE NEWS RELEASE for February 12, 2021 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended December 31, 2020 HILLSIDE, NEW JERSEY (February 12, 2021) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the |
|
| February 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 inbp202102118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 12, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPOR |
|
| February 12, 2021 |
10-Q 1 inbp2020123110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2020 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File N |
|
| January 22, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 inbp202101228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 22, 2021 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORA |
|
| January 22, 2021 |
Integrated BioPharma Announces Upgrade to OTCQX NEWS RELEASE for January 22, 2021 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| November 30, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 30, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 12, 2020 |
10-Q 1 inbp2020093010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission Fil |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 12, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 12, 2020 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2020 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2020 HILLSIDE, NEW JERSEY (November 12, 2020) - Integrated BioPharma, Inc. |
|
| November 9, 2020 |
8-K 1 inbp202011098k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 4, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORA |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| September 24, 2020 |
Integrated BioPharma Reports Results for its Fiscal Year Ended June 30, 2020 EX-99.1 2 ex204714.htm EXHIBIT 99.1 PRESS RELEASE Integrated BioPharma Reports Results for its Fiscal Year Ended June 30, 2020 HILLSIDE, NEW JERSEY (September 23, 2020) - Integrated BioPharma, Inc. (OTC QB: INBP) (the “Company”) reports its financial results for the fiscal year ended June 30, 2020. Revenues for the fiscal year ended June 30, 2020 were $52.8 million compared to $50.0 million for th |
|
| September 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 23, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMM |
|
| September 23, 2020 |
EXHIBIT 10.22.1 Amendment of Paycheck Protection Program Note, dated as of August 20, 2020, by and among Integrated BioPharma, Inc. and PNC Bank, National Association Effective as of June 5, 2020, Sections 2 and 3 of the Note were amended and restated to read as follows: “2. Structure; Payment Terms. During the Deferral Period, interest on the outstanding principal balance will accrue at the Fixed |
|
| September 23, 2020 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| September 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2020 ☐ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| May 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 13, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 14, 2020 |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2020 EX-99.1 2 ex186611.htm EXHIBIT 99.1 PRESS RELEASE DATED MAY 13, 2020 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2020 HILLSIDE, NEW JERSEY (May 13, 2020) - Integrated BioPharma, Inc. (OTC BB: INBP) (the “Company”) reports its financial results for the quarter ended March 31, 2020. Revenue for the quarter ended March 31, 2020 was $13.6 million compared to $14.1 million for |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| May 13, 2020 |
EX-10.1 2 ex185003.htm EXHIBIT 10.1 PAYROLL PROTECTION PROGRAM LOAN Paycheck Protection Program Term Note $1,639,300.00 April 29, 2020 FOR VALUE RECEIVED, INTEGRATED BIOPHARMA INC (the “Borrower”), with an address at 225 LONG AVENUE, BUILDING 15, HILLSIDE, NEW JERSEY 07205, promises to pay to the order of PNC BANK, NATIONAL ASSOCIATION (the “Bank”), in lawful money of the United States of America |
|
| February 12, 2020 |
INBP / Integrated BioPharma, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| February 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 12, 2020 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| February 12, 2020 |
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2019 NEWS RELEASE for February 12, 2020 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| December 3, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 2, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| November 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 13, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 13, 2019 |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2019 NEWS RELEASE for November 13, 2019 Contact: Dina Masi, CFO Integrated BioPharma, Inc. |
|
| November 13, 2019 |
INBP / Integrated BioPharma, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 28, 2019 |
INBP / Integrated BioPharma, Inc. DEF 14A - - FORM DEF 14A DEF 14A 1 inbp20191021def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate |
|
| September 16, 2019 |
Integrated BioPharma Reports Results for its Fiscal Year Ended June 30, 2019 EX-99.1 2 ex157836.htm EXHIBIT 99.1 PRESS RELEASE DATED SEPTEMBER 13, 2019 NEWS RELEASE for September 16, 2019 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Fiscal Year Ended June 30, 2019 HILLSIDE, NEW JERSEY (September 16, 2019) - Integrated BioPharma, Inc. (OTC BB: INBP) (the “Company” or “INBP”) reported fi |
|
| September 16, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 inbp201909138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 16, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPO |
|
| August 29, 2019 |
INBP / Integrated BioPharma, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2019 ☐ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act Of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| August 29, 2019 |
Subsidiaries of the Registrant EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation Manhattan Drug Company, Inc. New Jersey AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceuticals, |
|
| May 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 22, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 15, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 15, 2019 |
EXHIBIT 10.1 SECOND AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into May 15, 2019 by and among INTEGRATED BIOPHARMA, INC., a corporation organized under the laws of the State of Delaware (“Integrated”), InB:MANHATTAN DRUG COMPANY, INC., a corporation organized under the law |
|
| May 15, 2019 |
EXHIBIT 10.2 SECOND AMENDED AND RESTATED TERM NOTE PNC Bank, National Association $3,585,175.00 May 15, 2019 Woodbridge, New Jersey This Second Amended and Restated Term Note (this “Note”) is executed and delivered under and pursuant to the terms of that certain Revolving Credit, Term Loan and Security Agreement dated as of June 27, 2012 (as amended, supplemented, restated or modified from time to |
|
| May 15, 2019 |
INBP / Integrated BioPharma, Inc. 10-Q Quarterly Report FORM 10-Q 10-Q 1 inbp2019033110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Nu |
|
| May 15, 2019 |
EX-99.1 2 ex145031.htm EXHIBIT 99.1 PRESS RELEASE DATED MAY 15 2019 EARNINGS RELEASE AND REFINANCING NEWS RELEASE for May 15, 2019 Contact: Dina Masi, CFO Integrated BioPharma, Inc. [email protected] 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended March 31, 2019 and Announces Refinancing of its Senior Credit Facility with PNC Bank, National Association HILLSIDE, NEW |
|
| May 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 1, 2019 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISSION |
|
| May 6, 2019 |
Integrated BioPharma Names Christina Kay and Riva Sheppard as Co-Chief Executive Officers NEWS RELEASE for May 6, 2019 Contact: Dina Masi, CFO Integrated BioPharma, Inc. 888-319-6962 [email protected] Integrated BioPharma Names Christina Kay and Riva Sheppard as Co-Chief Executive Officers HILLSIDE, NEW JERSEY (May 6, 2019) - Integrated BioPharma, Inc. (OTC BB: INBP) (the “Company” or “INBP”) announced today that its Board of Directors (the “Board”) has appointed Ms. Christina K |
|
| February 13, 2019 |
INBP / Integrated BioPharma, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 inbp2018123110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2018 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File |
|
| December 28, 2018 |
INBP / Integrated BioPharma, Inc. FORM S-8 As filed with the Securities and Exchange Commission on December 28, 2018 Registration No. |
|
| November 26, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 inbp201811268k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 26, 2018 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPOR |
|
| November 9, 2018 |
INBP / Integrated BioPharma, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 29, 2018 |
INBP / Integrated BioPharma, Inc. FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| September 12, 2018 |
INBP / Integrated BioPharma, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2018 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact |
|
| September 12, 2018 |
Subsidiaries of the Registrant Exhibit 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation InB:Manhattan Drug Company, Inc. New York AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceutical |
|
| August 1, 2018 |
Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2018 Integrated BioPharma, Inc. |
|
| August 1, 2018 |
INTEGRATED BIOPHARMA ANNOUNCES CONVERSION OF $5,350,000 CONVERTIBLE DEBT TO EQUITY NEWS RELEASE for August 1, 2018 Contact: Dina Masi, CFO Integrated BioPharma, Inc 888-319-6962 investors@ibiopharma. |
|
| May 9, 2018 |
INBP / Integrated BioPharma, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 9, 2018 |
INBP / Integrated BioPharma, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2017 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| November 27, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 inbp201711278k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 27, 2017 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPOR |
|
| November 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA |
|
| October 27, 2017 |
Integrated BioPharma FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| September 1, 2017 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2017 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other juris |
|
| September 1, 2017 |
Subsidiaries of the Registrant (14 EX-21 2 ex21.htm EXHIBIT 21 Exhibit 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation InB:Manhattan Drug Company, Inc. New York AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jer |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, IN |
|
| February 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2016 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| November 28, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 28, 2016 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 21, 2016 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| November 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 28, 2016 |
Integrated BioPharma FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confiden |
|
| September 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2016 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| September 2, 2016 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Exhibit 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation InB:Manhattan Drug Company, Inc. New York AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey InB:Paxis Pharmaceutical |
|
| May 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 19, 2016 |
EX-10.2 7 exhibit102.htm Exhibit 10.2 AMENDED AND RESTATED TERM NOTE PNC Bank, National Association $3,422,160 February , 2016 Woodbridge, New Jersey This Amended and Restated Term Note (this "Note") is executed and delivered under and pursuant to the terms of that certain Revolving Credit, Term Loan and Security Agreement dated as of June 27, 2012 (as amended, supplemented, restated or modified f |
|
| February 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 19, 2016 |
Exhibit 10.1 FIRST AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT (this "Agreement") is entered into February 19, 2016 by and among INTEGRATED BIOPHARMA, INC., a corporation organized under the laws of the State of Delaware ("Integrated"), InB:MANHATTAN DRUG COMPANY, INC., a corporation organized under the |
|
| February 19, 2016 |
Exhibit 10.3 FIRST AMENDMENT TO PROMISSORY NOTE This FIRST AMENDMENT TO PROMISSORY NOTE, dated as of February 19, 2016 (this "Amendment"), among INTEGRATED BIOPHARMA, INC., a Delaware corporation (the "Company"), INB:MANHATTAN DRUG COMPANY, INC., a New York corporation ("MDC", and together with the Company, collectively, the "Loan Parties", and each, a "Loan Party"), and VITAMIN REALTY ASSOCIATES, |
|
| February 19, 2016 |
EX-10.4 9 exhibit104.htm Exhibit 10.4 FIRST AMENDMENT TO NOTES This FIRST AMENDMENT TO NOTES, dated as of February 19, 2016 (this "Amendment"), among INTEGRATED BIOPHARMA, INC., a Delaware corporation (the "Company"), AGROLABS, INC., a New Jersey corporation ("AgroLabs"), IHT HEALTH PRODUCTS, INC., a Delaware corporation ("IHT Health"), IHT PROPERTIES CORP., a Delaware corporation ("IHT Properties |
|
| February 16, 2016 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): 0 Form 10-K ? Form 11-K ? Form 20-F x Form 10-Q ? Form N-SAR For Period Ending: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ? Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| November 30, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 30, 2015 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| October 26, 2015 |
inbproxy2015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Sta |
|
| September 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2015 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| September 4, 2015 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT EX-21 36 exhibit21.htm Exhibit 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation InB:Manhattan Drug Company, Inc. New York AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey I |
|
| June 5, 2015 |
inb8k20150605.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 2, 2015 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2 |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| December 1, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 1, 2014 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHAR |
|
| November 7, 2014 |
Exhibit 10.2 Cross Collateralization Agreement THIS CROSS COLLATERALIZATION AGREEMENT (this “Agreement”) is made as of this 22nd day of September, 2014, by and among INB:MANHATTAN DRUG COMPANY, INC. (the “Grantor”), PNC BANK, NATIONAL ASSOCIATION (“Creditor A”) and PNC EQUIPMENT FINANCE, LLC (“Creditor B”). WHEREAS, the Grantor and Creditor A have entered into, or may hereafter enter into, certain |
|
| November 7, 2014 |
Exhibit 10.3 SECURITY AGREEMENT (All Personal Property and Fixtures) Borrower/Lessee Grantor This Security Agreement (together with all amendments, supplements and other modifications, this "Agreement") executed in Hillside, New Jersey, as of this 22nd day of September, 2014, by INB:MANHATTAN DRUG COMPANY, INC. (together with its permitted successors and assigns, heirs and personal representatives |
|
| November 7, 2014 |
Exhibit 10.1 Convertible Line of Credit Note $350,000.00 September 22, 2014 Loan # 185394000 /185394001 FOR VALUE RECEIVED, INB:MANHATTAN DRUG COMPANY, INC. (?Borrower?), with an address at 225 Long Ave., Hillside, NJ 07205, promises to pay to the order of PNC EQUIPMENT FINANCE, LLC (?Lender?), in lawful money of the United States of America in immediately available funds at its offices located at |
|
| November 7, 2014 |
Exhibit 10.4 Guaranty and Suretyship Agreement THIS GUARANTY AND SURETYSHIP AGREEMENT (this “Guaranty”) is made and entered into as of this 22nd day of September, 2014, by INTEGRATED BIOPHARMA, INC. (the “Guarantor”), with an address at 225 Long Ave., Hillside, NJ 07205, in consideration of the extension of credit by PNC EQUIPMENT FINANCE, LLC (“PNCEF”), with an address at 995 Dalton Ave, Cincinna |
|
| October 28, 2014 |
INBP / Integrated BioPharma, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confiden |
|
| September 8, 2014 |
Exhibit 10.4.1 AMENDMENT OF LEASE THIS AMENDMENT OF LEASE (this ?Amendment?), made as of the 19th day of May 2014 (the ?Effective Date?), by and between VITAMIN REALTY ASSOCIATES, L.L.C., having an address 250 Route 22 a/k/a 225 Long Avenue, Township of Hillside, Union County, New Jersey (the ?Landlord?), and AGROLABS, INC, having an address at 225 Long Avenue, Building 15 (2nd Floor), Hillside, N |
|
| September 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2014 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| September 8, 2014 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT EX-21 31 exhibit21.htm Exhibit 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT Subsidiary Name State of Incorporation InB:Manhattan Drug Company, Inc. New York AgroLabs, Inc. New Jersey IHT Health Products, Inc. Delaware Vitamin Factory, Inc. Delaware IHT Properties, Inc. Delaware The Organic Beverage Company – inactive New Jersey InB:Paxis Pharmaceuticals, Inc. (f/k/ |
|
| May 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, IN |
|
| February 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q/A (Amendment No. 1) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 I |
|
| February 12, 2014 |
Integrated BioPharma (Quarterly Report) 10-Q 1 inb10q20131231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-3 |
|
| December 2, 2013 |
Submission of Matters to a Vote of Security Holders 8-K 1 inb8k20131202.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 2, 2013 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001- |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA |
|
| November 6, 2013 |
DEFA14A 1 inbproxy2013a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Prelimi |
|
| October 28, 2013 |
DEF 14A 1 inbproxy2013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminar |
|
| September 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2013 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| September 30, 2013 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT |
|
| May 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, IN |
|
| February 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2012 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| February 14, 2013 |
NT 10-Q 1 inb12b2520130214.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 11-K o Form 20-F T Form 10-Q o Form N-SAR For Period Ending: December 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N- |
|
| November 27, 2012 |
Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 26, 2012 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA |
|
| November 14, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 11-K o Form 20-F T Form 10-Q o Form N-SAR For Period Ending: September 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| November 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confid |
|
| October 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2012 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| October 15, 2012 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT |
|
| September 28, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One):T Form 10-K o Form 11-K o Form 20-F o Form 10-Q o Form N-SAR For Period Ending: June 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| June 29, 2012 |
Exhibit 10.6 STOCK PLEDGE AGREEMENT THIS STOCK PLEDGE AGREEMENT ("Pledge Agreement") made this 27th day of June, 2012 by and between INTEGRATED BIOPHARMA, INC., a Delaware corporation having an address at 225 Long Avenue, Building 15, P.O. Box 278, Hillside, New Jersey 07025 (the “Pledgor”), and PNC BANK, NATIONAL ASSOCIATION, as Agent for the Lenders, having an office at Two Tower Center Boulevar |
|
| June 29, 2012 |
Exhibit 99.1 NEWS RELEASE for June 29, 2012 Contact: Dina Masi, CFO Integrated BioPharma, Inc 888-319-6962 [email protected] INTEGRATED BIOPHARMA ANNOUNCES CLOSING OF $11.7 MILLION REVOLVING CREDIT FACILITY AND REFINANCING OF SUBORDINATED DEBT HILLSIDE, NEW JERSEY (June 29, 2012) - Integrated BioPharma, Inc. (OTC BB: INBP) announced today the closing of a new five year $11.7 million revolvi |
|
| June 29, 2012 |
Exhibit 10.9 Environmental Indemnity Agreement THIS ENVIRONMENTAL INDEMNITY AGREEMENT (the “Agreement”) is made as of the 27th day of June, 2012, by INTEGRATED BIOPHARMA, INC., a corporation of the State of Delaware (“Integrated”), InB:MANHATTAN DRUG COMPANY, INC., a corporation of the State of New York (“MD”), AGROLABS, INC., a corporation of the State of New Jersey (“AL”), IHT HEALTH PRODUCTS, I |
|
| June 29, 2012 |
AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT Exhibit 10.10 AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT, dated as of June 27, 2012, is by and between INTEGRATED BIOPHARMA, INC., a Delaware corporation (the “Company”), and CD FINANCIAL, LLC, a Florida limited liability company (the “Investor” or “CD Financial”). PRELIMINARY STATEMENT: A. The Company and the Investor entered into th |
|
| June 29, 2012 |
Exhibit 10.3 REVOLVING CREDIT NOTE PNC Bank, National Association $8,000,000 June 27, 2012 Woodbridge, N.J. This Revolving Credit Note (this “Note”) is executed and delivered under and pursuant to the terms of that certain Revolving Credit, Term Loan and Security Agreement dated as of the date hereof (as amended, restated, supplemented or modified from time to time, the “Loan Agreement”) by and am |
|
| June 29, 2012 |
EX-10.8 9 exhibit108.htm Exhibit 10.8 Mortgage and Security Agreement THIS MORTGAGE AND SECURITY AGREEMENT (this “Mortgage”) is made as of the 27th day of June, 2012, by IHT PROPERTIES CORP., a Delaware corporation (the “Mortgagor”), with an address at 225 Long Avenue, Building 15, P.O. Box 278, Hillside, New Jersey 07205 in favor of PNC BANK, NATIONAL ASSOCIATION as Agent for the Lenders (the “Mo |
|
| June 29, 2012 |
Exhibit 10.14 INTEGRATED BIOPHARMA, INC. PROMISSORY NOTE THIS PROMISSORY NOTE DOES NOT REQUIRE PHYSICAL SURRENDER HEREOF IN ORDER TO EFFECT A PARTIAL PAYMENT HEREOF. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS NOTE MAY BE LESS THAN THE PRINCIPAL AMOUNT SHOWN BELOW. $1,714,000.00 Issue Date: June 27, 2012 New York, New York FOR VALUE RECEIVED, INTEGRATED BIOPHARMA, INC., a Delaware corpor |
|
| June 29, 2012 |
Exhibit 10.15 PROMISSORY NOTE $685,985.61 Issue Date: June 27, 2012 New York, New York FOR VALUE RECEIVED, INB:MANHATTAN DRUG COMPANY, INC., a New York corporation (“MDC”), and INTEGRATED BIOPHARMA, INC., a Delaware corporation (“Integrated”) (MDC and Integrated are jointly and severally referred to herein as the “Company”), hereby, jointly and severally, promise to pay to the order of VITAMIN REA |
|
| June 29, 2012 |
Exhibit 10.7 INTERCREDITOR AND SUBORDINATION AGREEMENT THIS INTERCREDITOR AND SUBORDINATION AGREEMENT (this “Subordination Agreement”) is made as of the 27th day of June, 2012 by and between PNC BANK, NATIONAL ASSOCIATION, as Agent for Lenders (the "Bank”) and CD Financial, LLC, a Florida limited liability company having its principal place of business at 3299 NW Second Avenue, Boca Raton, Florida |
|
| June 29, 2012 |
Exhibit 10.11 AMENDED AND RESTATED SECURITY AGREEMENT This AMENDED AND RESTATED SECURITY AGREEMENT, dated as of June 27, 2012, is by and among Integrated BioPharma, Inc., a Delaware corporation (the “Company”), each of the Subsidiaries of the Company party hereto from time to time, whether as an original signatory hereto or as an Additional Debtor (as defined in Section 4.5 below) (such Subsidiari |
|
| June 29, 2012 |
Exhibit 10.1 REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT PNC BANK, NATIONAL ASSOCIATION (AS LENDER AND AS AGENT) WITH INTEGRATED BIOPHARMA, INC., InB:MANHATTAN DRUG COMPANY, INC., AGROLABS, INC., IHT HEALTH PRODUCTS, INC., IHT PROPERTIES CORP. AND VITAMIN FACTORY, INC. (BORROWERS) June 27, 2012 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 1.1 Accounting Terms 1 1.2 General Terms 1 1.3 Un |
|
| June 29, 2012 |
Exhibit 10.12 AMENDED AND RESTATED SUBSIDIARY GUARANTEE This AMENDED AND RESTATED SUBSIDIARY GUARANTEE, dated as of June 27, 2012 (as amended, restated, modified or supplemented from time to time, this “Guarantee”), is by each of the Subsidiaries (as defined in the Securities Purchase Agreement referred to below) of Integrated BioPharma, Inc., a Delaware corporation (the “Company”) party hereto fr |
|
| June 29, 2012 |
EX-10.4 5 exhibit104.htm Exhibit 10.4 CONTINUING LIMITED GUARANTY THIS CONTINUING LIMITED GUARANTY (this “Guaranty”) dated as of June 27, 2012 made by CARL DeSANTIS (the “Guarantor”), in favor of PNC BANK, NATIONAL ASSOCIATION, a National Banking Association organized under the laws of the United States of America, having an office located at PNC Bank Center, Two Tower Center Boulevard, East Bruns |
|
| June 29, 2012 |
Exhibit 10.5 CONTINUING LIMITED GUARANTY THIS CONTINUING LIMITED GUARANTY (this “Guaranty”) dated June 27th, 2012 made by E. GERALD KAY (the “Guarantor”), in favor of PNC BANK, NATIONAL ASSOCIATION, a National Banking Association organized under the laws of the United States of America, having an office located at PNC Bank Center, Two Tower Center Boulevard, East Brunswick, New Jersey 08816, as Ag |
|
| June 29, 2012 |
Exhibit 10.2 TERM NOTE PNC Bank, National Association $3,727,000 June 27, 2012 Woodbridge, New Jersey This Term Note (this “Note”) is executed and delivered under and pursuant to the terms of that certain Revolving Credit, Term Loan and Security Agreement dated as of the date hereof (as amended, supplemented, restated or modified from time to time, the “Loan Agreement”) by and among INTEGRATED BIO |
|
| June 29, 2012 |
Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2012 Integrated BioPharma, Inc. |
|
| June 29, 2012 |
Exhibit 10.13 INTEGRATED BIOPHARMA, INC. AMENDED AND RESTATED CONVERTIBLE SECURED PROMISSORY NOTE THIS AMENDED AND RESTATED CONVERTIBLE SECURED PROMISSORY NOTE DOES NOT REQUIRE PHYSICAL SURRENDER HEREOF IN ORDER TO EFFECT A PARTIAL PAYMENT HEREOF. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS NOTE MAY BE LESS THAN THE PRINCIPAL AMOUNT SHOWN BELOW. $5,350,000.00 Issue Date: June 27, 2012 Ne |
|
| May 21, 2012 |
Exhibit 10.2 LEASE AGREEMENT This Agreement is made on January 5, 2012 BETWEEN VITAMIN REALTY ASSOCIATES, LLC located at 225 Long Avenue, Building 15, Hillside, NJ 07205 herein designated as the "Landlord", AND AGRO LABS, INC Located at 225 Long Avenue, Building 15 (2nd Floor), Hillside, NJ 07205 herein designated as the "Tenant." 1. Premises. The Landlord does hereby lease to the Tenant and the T |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2012 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA, |
|
| May 21, 2012 |
Exhibit 10.3 STOCK PURCHASE AGREEMENT BY AND AMONG CEDARBURG PHARMACEUTICALS, INC., PURCHASER, INB: HAUSER PHARMACEUTICAL SERVICES, INC., COMPANY, INB: PAXIS PHARMACEUTICALS, INC., AND INTEGRATED BIOPHARMA, INC., SELLER, DATED: March 17, 2009 i EXHIBITS Exhibit A Capitalization Table Exhibit B Secretary's Certificate for the Company Exhibit C Secretary's Certificate for the Purchaser Exhibit 2.01( |
|
| May 21, 2012 |
EX-10.1 23 exhibit101.htm Exhibit 10.1 SECOND AMENDMENT OF LEASE This SECOND AMENDMENT OF LEASE (this “Amendment”) is made as of the 5th day of January, 2012, between VITAMIN REALTY ASSOCIATES LLC (the LESSOR”), a New Jersey limited liability company, and MANHATTAN DRUG COMPANY ( the LESSEE”), a New Jersey corporation, having an address at 225 Long Avenue, Hillside, New Jersey 07205. W I T N E S S |
|
| May 16, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 11-K o Form 20-F T Form 10-Q o Form N-SAR For Period Ending: March 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| February 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2011 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARM |
|
| February 14, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 11-K o Form 20-F x Form 10-Q o Form N-SAR For Period Ending: December 31, 2011 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| February 3, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.1 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 30, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Imper |
|
| February 3, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 30, 2012 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMIS |
|
| January 26, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.2 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 24, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Imper |
|
| January 26, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 EX-10.1 2 exhibit101.htm Exhibit 10.1 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 20, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. |
|
| January 26, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 inb8k20120124.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 20, 2012 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001- |
|
| January 12, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.1 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 9, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Imperi |
|
| January 12, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.2 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 11, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Imper |
|
| January 12, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 9, 2012 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMISS |
|
| January 5, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 29, 2011 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| January 5, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.2 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 January 5, 2012 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Imperi |
|
| January 5, 2012 |
IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 Exhibit 10.1 IMPERIUM ADVISERS, LLC 515 Madison Avenue New York, NY 10022 December 29, 2011 Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 Re: Extension of Forbearance Agreement Ladies and Gentlemen: Reference is made to the Forbearance Agreement, dated as of October 4, 2011 (as amended, the “Forbearance Agreement”), by and between Integrated BioPharma, Inc. (the “Company”) and Impe |
|
| November 28, 2011 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 28, 2011 INTEGRATED BIOPHARMA, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) 001-31668 22-2407475 (COMMI |
|
| November 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2011 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA |
|
| November 14, 2011 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One):o Form 10-K o Form 11-K o Form 20-F T Form 10-Q o Form N-SAR For Period Ending: September 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| October 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 13, 2011 |
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES SUBSIDIARIES OF THE REGISTRANT |
|
| October 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K Annual Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2011 Commission File Number 001-31668 INTEGRATED BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 22-2407475 (State or other jurisdiction of incorporation or organization) (I |
|
| October 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 4, 2011 Integrated BioPharma, Inc. |
|
| October 11, 2011 |
Exhibit 10.1 FORBEARANCE AGREEMENT THIS FORBEARANCE AGREEMENT (this ?Agreement?), dated as of October 4, 2011, is entered into by and between Integrated BioPharma, Inc. (the ?Company?) and Imperium Advisers, LLC, in its capacity as collateral agent (in such capacity, ?Collateral Agent?) for Investors (as defined below). W I T N E S S E T H: WHEREAS, pursuant to the (1) Amended and Restated Securit |
|
| September 28, 2011 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-31668 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 11-K o Form 20-F o Form 10-Q o Form N-SAR For Period Ending: June 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SAR o Transition Report on Form 11-K Read the attached instruction sheet before preparing form. |
|
| May 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q x X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2011 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-31668 INTEGRATED BIOPHARMA |
